Urapidil treatment decreases plasma fibrinogen concentration in essential hypertension

Metabolism: Clinical and Experimental

Volumn 45, Issue 10, 1996, Pages 1221-1229

  Haenni, Arvo ^a   Lithell, Hans ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; FIBRINOGEN; URAPIDIL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; FIBRIN FORMATION; FIBRINOGEN BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029816562     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(96)90239-5     Document Type: Article

References (56)

1. Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke, and coronary heart disease. Lancet 335:827-838, 1990
2. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 265:3255-3264, 1991
3. Dahlöf B, Lindholm LH, Hansson L, et al: Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP-Hypertension) Lancet 338:1281-1285, 1991
4. MRC Working Party: Medical Research Council trial of treatment of hypertension in older adults: Principal results. Br Med J 304:405-412, 1992
5. Pollare T, Lithell H, Berne C: Insulin resistance is a characteristic feature of primary hypertension independently of obesity. Metabolism 39:167-174, 1990
6. DeFronzo R, Ferranninni E: Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic disease. Diabetes Care 14: 173-194, 1991
7. Pollare T, Lithell H, Selinus I, et al: Sensitivity to insulin during treatment with atenolol and metoprolol: A randomised, double-blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J 298:1152-1157, 1989
8. Pollare T, Lithell H, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 321:868-873, 1989
9. Leren P, Foss OP, Helgeland A, et al: Effects of propranolol and prazosin on blood lipids. The Oslo Study. Lancet 2:4-6, 1980
10. Lithell H, Berne C, Waern U, et al: Glucose metabolism during long-term treatment with prazosin. Diabetes Res 2:297-299, 1985
11. Pollare T, Lithell H, Selinus I, et al: Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 31:415-420, 1988
12. Fozard JR, Mir AK: Are 5-HT-receptors involved in the antihypertensive effects of urapidil? Br J Pharmacol 90:24P, 1987
13. Sanders KH, Beller KD, Bischler P, et al: Interactions of urapidil with brain serotonin 1A receptors increase the blood pressure reduction due to peripheral alpha-adrenoceptor inhibition. J Hypertens 6:S65-S68, 1988 (suppl)
14. Mandai AK, Kellar KJ, Friedman E, et al: Importance of central nervous system serotonin 1A receptors for mediating the hypotensive effects of urapidil. J Pharmacol Exp Ther 251:563-570, 1989
15. Shebuski RJ, Zimmerman BG: Suppression of reflex tachycardia following alpha-adrenoceptor blockade in conscious dogs: Comparison of urapidil with prazosin. J Cardiovasc Pharmacol 6:788-794, 1984
16. van Zwieten PA: Different types of centrally acting antihypertensive drugs. Eur Heart J 13:18-21, 1992 (suppl A)
17. Moore N, Fresel J, Johanides R, et al: Compared hemodynamic effects of urapidil, prazosin and clonidine at rest and during exercise in healthy volunteers. Blood Pressure 3:7-12, 1994 (suppl 4)
18. Grassi D, Seravalle G, Mancia G, et al: Hemodynamic and neural effects of urapidil and prazosin in essential hypertensives. Blood Pressure 3:13-18, 1994 (suppl 4)
19. De Fronzo RA, Tobin JD, Andres R: Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 237:214-233, 1979
20. Pollare T, Lithell H, Vessby B: Lipoprotein lipase activity in skeletal muscle is related to insulin sensitivity. Arterioscler Thromb 11:1192-1203, 1991
21. Zech K, Huber R: Determination of urapidil and its metabolites in human serum and urine: Comparison of liquid-liquid and fully automated liquid-solid extraction. J Chromatogr 353:351-360, 1986
22. Kannel WB, Wolf PA, Castelli WP, et al: Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 258:1183-1186, 1987
23. Ernst E, Resch KL: Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med 118:956-963, 1993
24. Thompson SG, Kienast J, Pyke SDM, et al: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 332:635-641, 1995
25. Lipinska I, Gurewich V, Meriam CM: Lipids, lipoproteins, fibrinogen and flbrinolytic activity in angiographically assessed coronary heart disease. Artery 15:44-60, 1987
26. Wiseman S, Kenchington G, Dain R, et al: Influence of smoking and plasma factors on patency of femoropopliteal vein grafts. Br Med J 299:643-646, 1989
27. Laurell CB, Lundh B, Nosslin B: Clinical Chemistry in Medical Practice. Lund, Sweden, Studentlitteratur, 1980, pp 294-296
28. Hermann JM, Mayer EO: A long-term study of the effects of celiprolol on blood pressure and lipid-associated risk factors. Am Heart J 116:1416-1421, 1988
29. Mehrotra TN, Mital HS, Singh VS, et al: Platelet adhesiveness, plasma fibrinogen and fibrinolytic activity in angina pectoris before and after propranolol therapy. J Assoc Phys India 31:641-643, 1983
30. Hamsten A, Wiman B, de Faire U, et al: Increased plasma level of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313:1557-1563, 1985
31. Hamsten A, Walldius G, Szamosi A, et al: Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 2:3-9, 1987
32. Jansson JH, Johansson B, Boman K, et al: Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol. Eur J Clin Pharmacol 40:321-326, 1991
33. Landin K, Tengborn L, Smith U: Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Int Med 227:273-278, 1990
34. Vague P, Juhan-Vague I, Aillaud MF, et al: Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 2:250-253, 1986
35. Mykkänen L, Rönnemaa T, Marniemi J, et al: Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 14:1264-1271, 1994
36. Cigolini M, Targher G, Seidell JC, et al: Relationships of plasminogen activator inhibitor-1 to anthropometry, serum insulin, triglycerides and adipose tissue fatty acids in healthy men. Atherosclerosis 106:139-147, 1994
37. Stiko-Rahm A, Wiman B, Hamsten A, et al: Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 10:1067-1073, 1990
38. Vague P, Juhan-Vague I: Insulin and the fibrinolytic system. A link between metabolism and thrombogenesis, in Smith U, Bruun NE, Hedner T, et al (eds): Hypertension as an Insulin-Resistant Disorder - Genetic Factors and Cellular Mechanisms. Novo Nordisk Foundation Symposium No. 5. International Congress Series 980, Amsterdam, the Netherlands, Excerpta Medica, 1991, pp 321-355
39. Gerber A, Weidmann C, Marone D: Cardiovascular and metabolic profile during intervention with urapidil in humans. Hypertension 7:963-971, 1985
40. Liebau H, Solleder P, Wurst W: Long-term antihypertensive treatment with urapidil. Curr Opin Cardiol 4:S57-S62,1989 (suppl 4)
41. Ferrara LA, Leonetti G, Fogari R, et al: Urapidil in hypercholesterolemic hypertensive patients. Blood Pressure 3:39-44, 1994 (suppl 4)
42. Hansson L: Treatment of hypertension in the elderly with special reference to urapidil. Blood Pressure 3:45-48, 1994 (suppl 4)
43. Pattenier JW, von Heusinger FC: Effects of urapidil treatment on lipid metabolism in patients with hypertension. Central and peripheral sympathetic mechanisms in hypertension: Pathophysiological and therapeutic aspects, in van Zwieten PA (ed): Focus on Urapidil. London, England, Royal Society of Medicine Services International Congress and Symposium Series No. 196, 1992, pp 61-66
44. Fariello R, Boni E, Corda L, et al: Influence of a new multifactorial antihypertensive on blood pressure and metabolic profile in essential hypertension associated with non-insulin-dependent diabetes mellitus. Eur Heart J 13:65-69, 1992 (suppl A)
45. Rubba P, Simone BD, Marotta T, et al: Adrenergic blocking agents and lipoprotein lipase activity. J Endocrinol Invest 12:119-122, 1989
46. Ferrara LA, Marotta T, Rubba P, et al: Effects of alpha-adrenergic and beta-adrenergic receptor blockade on lipid metabolism. Am J Med 80:104-108, 1986 (suppl 2A)
47. Andersson PE, Lithell H: Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. Relationship to changes in skeletal muscle blood flow. Am J Hypertens 9:323-333, 1996
48. Weidmann P, Ferrier C, Saxenhofer H, et al: Serum lipoproteine during treatment with antihypertensive drugs. Drugs 35:118-134, 1988 (suppl 6)
49. 1 adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity. J Hum Hypertens 8:219-226, 1994
50. Haenni A, Lithell H: Treatment with a beta-blocker with beta 2 agonism improves glucose and lipid metabolism in essential hypertension. Metabolism 43:455-461, 1994
51. Haenni A, Andersson PE, Lind L, et al: Electrolyte changes and metabolic effects of lisinopril/bendrofluazide treatment. Am J Hypertens 7:615-622, 1994
52. Lind L, Berne C, Pollare T, et al: Metabolic effects of antihypertensive treatment with nifedipine or furosemide. J Hum Hypertens 9:137-141, 1995
53. Pollare T, Lithell H, Mörlin C, et al: Metabolic effects of diltiazem and atenolol: Results from a randomized double-blind study with parallel groups. J Hypertens 7:551-559, 1989
54. Reneland R, Andersson PE, Haenni A, et al: Metabolic effects of long-term angiotensin-converting enzyme inhibition with fosinopril in patients with essential hypertension: Relationship to angiotensin-converting enzyme inhibition. Eur J Clin Pharmacol 46:431-436, 1994
55. Haenni A, Nilsson P, Andersson PE, et al: Insulin sensitivity changes after atenolol treatment depend on dose, duration and initial insulin sensitivity level, (in press)
56. Stanaszek WF, Kellerman D, Brogden RN, et al: Prazosin update: A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure. Drugs 25:339-384, 1983